STERIS (STE) Stock Forecast, Price & News

STERIS (NYSE:STE) Frequently Asked Questions

Is STERIS a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STERIS stock.
View analyst ratings for STERIS or view top-rated stocks.

Are investors shorting STERIS?

STERIS saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 950,900 shares, a drop of 23.9% from the April 15th total of 1,250,000 shares. Based on an average daily volume of 486,300 shares, the short-interest ratio is currently 2.0 days.
View STERIS's Short Interest.

When is STERIS's next earnings date?

STERIS is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for STERIS.

How were STERIS's earnings last quarter?

STERIS plc (NYSE:STE) issued its quarterly earnings results on Tuesday, November, 2nd. The medical equipment provider reported $1.99 EPS for the quarter, beating the consensus estimate of $1.82 by $0.17. The medical equipment provider earned $1.20 billion during the quarter, compared to the consensus estimate of $1.16 billion. STERIS had a net margin of 5.32% and a trailing twelve-month return on equity of 11.83%. During the same quarter in the previous year, the firm earned $1.48 EPS.
View STERIS's earnings history.

How often does STERIS pay dividends? What is the dividend yield for STERIS?

STERIS announced a quarterly dividend on Wednesday, May 4th. Stockholders of record on Tuesday, June 14th will be paid a dividend of $0.43 per share on Tuesday, June 28th. This represents a $1.72 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date is Monday, June 13th.
View STERIS's dividend history.

Is STERIS a good dividend stock?

STERIS pays an annual dividend of $1.72 per share and currently has a dividend yield of 0.80%. STERIS has been increasing its dividend for 17 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of STERIS is 71.97%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, STERIS will have a dividend payout ratio of 17.50% next year. This indicates that STERIS will be able to sustain or increase its dividend.
View STERIS's dividend history.

What guidance has STERIS issued on next quarter's earnings?

STERIS issued an update on its FY 2023 earnings guidance on Wednesday, May, 11th. The company provided earnings per share (EPS) guidance of $8.55-$8.75 for the period, compared to the consensus EPS estimate of $8.19. The company issued revenue guidance of -.

What price target have analysts set for STE?

6 Wall Street analysts have issued 1-year target prices for STERIS's shares. Their forecasts range from $250.00 to $275.00. On average, they anticipate STERIS's share price to reach $264.00 in the next year. This suggests a possible upside of 21.1% from the stock's current price.
View analysts' price targets for STERIS or view top-rated stocks among Wall Street analysts.

Who are STERIS's key executives?

STERIS's management team includes the following people:

• Mr. Daniel A. Carestio, Pres, CEO & Director (Age 49, Pay $1.44M) (LinkedIn Profile)
• Mr. Michael J. Tokich, Sr. VP & CFO (Age 53, Pay $1.23M) (LinkedIn Profile)
• Mr. John Adam Zangerle, Sr. VP, Gen. Counsel, Sec. (Age 55, Pay $940.38k) (LinkedIn Profile)
• Mr. Walter M. Rosebrough Jr., CEO Emeritus & Sr. Advisor (Age 68, Pay $2.65M) (LinkedIn Profile)
• Mr. Cary L. Majors, Sr. VP of North America Commercial Operations (Age 47, Pay $851.27k) (LinkedIn Profile)
• Ms. Karen L. Burton, Chief Accounting Officer, VP & Controller (Age 54) (LinkedIn Profile)
• Julie Winter, VP of Investor Relations & Corp. Communications
• Ms. Mary Clare Fraser, VP & Chief HR Officer (Age 52)
• Ms. Julia K. Madsen, Sr. VP of Life Sciences (Age 57) (LinkedIn Profile)
• Mr. Renato G. Tamaro, VP & Corp. Treasurer (Age 53) (LinkedIn Profile)

What is Walter M. Rosebrough, Jr.'s approval rating as STERIS's CEO?

196 employees have rated STERIS CEO Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among STERIS's employees.

Who are some of STERIS's key competitors?

Some companies that are related to STERIS include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Hologic (HOLX), Insulet (PODD), Teleflex (TFX) and Abiomed (ABMD).
View all of STE's competitors.

What other stocks do shareholders of STERIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).

What is STERIS's stock symbol?

STERIS trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."

Who are STERIS's major shareholders?

STERIS's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.51%), BlackRock Inc. (8.18%), WCM Investment Management LLC (6.46%), Massachusetts Financial Services Co. MA (4.36%), State Street Corp (4.22%) and APG Asset Management N.V. (3.43%). Company insiders that own STERIS stock include Cary L Majors, Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, David B Lewis, Jacqueline B Kosecoff, John Adam Zangerle, Julia Madsen, Karen L Burton, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard C Breeden and Walter M Rosebrough Jr.
View institutional ownership trends for STERIS.

Which institutional investors are selling STERIS stock?

STE stock was sold by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, WCM Investment Management LLC, Mackenzie Financial Corp, UBS Group AG, Bank of Nova Scotia, RMB Capital Management LLC, Strs Ohio, and Federated Hermes Inc.. Company insiders that have sold STERIS company stock in the last year include Cary L Majors, Cynthia L Feldmann, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Michael J Tokich, and Renato Tamaro.
View insider buying and selling activity for STERIS or view top insider-selling stocks.

Which institutional investors are buying STERIS stock?

STE stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., Great West Life Assurance Co. Can, Sumitomo Mitsui Trust Holdings Inc., JPMorgan Chase & Co., Assenagon Asset Management S.A., Vanguard Group Inc., Jennison Associates LLC, and Massachusetts Financial Services Co. MA.
View insider buying and selling activity for STERIS or or view top insider-buying stocks.

How do I buy shares of STERIS?

Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is STERIS's stock price today?

One share of STE stock can currently be purchased for approximately $218.07.

How much money does STERIS make?

STERIS has a market capitalization of $21.83 billion and generates $4.59 billion in revenue each year. The medical equipment provider earns $397.40 million in net income (profit) each year or $2.389990 on an earnings per share basis.

How many employees does STERIS have?

STERIS employs 13,000 workers across the globe.

When was STERIS founded?

STERIS was founded in 1987.

What is STERIS's official website?

The official website for STERIS is www.steris.com.

How can I contact STERIS?

STERIS's mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider can be reached via phone at (531) 232-2000, via email at [email protected], or via fax at 440-639-4457.